Eric Ko to Humans
This is a "connection" page, showing publications Eric Ko has written about Humans.
Connection Strength
0.274
-
Ko EC, Hanna GJ. Immunotherapy for head and neck cancer: where do we go from here? Immunotherapy. 2023 12; 15(18):1497-1500.
Score: 0.034
-
Agrawal V, Benjamin KT, Ko EC. Radiotherapy and Immunotherapy Combinations for Lung Cancer. Curr Oncol Rep. 2020 11 19; 23(1):4.
Score: 0.028
-
Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019 07; 95(7):936-939.
Score: 0.025
-
Ko E. Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non-Small-Cell Lung Cancer. Oncology (Williston Park). 2018 09 15; 32(9):460-2.
Score: 0.024
-
Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5792-5806.
Score: 0.023
-
Ko EC, Michaud AL, Valicenti RK. Postoperative Radiation After Radical Prostatectomy. Semin Radiat Oncol. 2017 01; 27(1):50-66.
Score: 0.021
-
Ko EC, Liu JT, Stone NN, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiother Oncol. 2014 Feb; 110(2):261-7.
Score: 0.017
-
Ko EC, Genden EM, Misiukiewicz K, Som PM, Kostakoglu L, Chen CT, Packer S, Kao J. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep. 2012 Feb; 27(2):467-74.
Score: 0.015
-
Ko EC, Stone NN, Stock RG. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):600-7.
Score: 0.015
-
Ko EC, Koprowski CD, Dickson-Witmer D, Penman E, Sorensen M, Hanlon AL, Sammons S, Farach A, Strasser J. Partial vs. whole breast irradiation in a community hospital: a retrospective cohort analysis of 200 patients. Brachytherapy. 2010 Jul-Sep; 9(3):248-53.
Score: 0.013
-
Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol. 2003 Dec; 132(4):294-309.
Score: 0.009
-
Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):695-701.
Score: 0.006
-
Wei XX, Ko EC, Ryan CJ. Treatment strategies in low-volume metastatic castration-resistant prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):596-603.
Score: 0.006
-
Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M, Sung M, Ferris R, Kao J, Wang LH, Pan PY, Ko EC, Chen SH. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res. 2015 Sep 15; 21(18):4073-4085.
Score: 0.005
-
Carpenter TJ, Kann B, Buckstein MH, Ko EC, Bakst RL, Misiukiewicz KJ, Posner MR, Genden EM, Gupta V. Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2014 Nov; 123(11):791-7.
Score: 0.004
-
D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10.
Score: 0.004
-
Fu S, Yang Y, Das TK, Tirtha D, Yen Y, Zhou BS, Zhou MM, Ohlmeyer M, Ko EC, Cagan R, Rosenstein BS, Chen SH, Kao J. ?-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers. PLoS One. 2012; 7(6):e38465.
Score: 0.004
-
Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One. 2012; 7(6):e36979.
Score: 0.004
-
Tong CC, Lau KH, Rivera M, Cannan D, Aguirre-Ghiso J, Sikora AG, Gupta V, Forsythe K, Ko EC, Misiukiewicz K, Gurudutt V, Teng MS, Packer SH, Genden EM, Kao J. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. 2012 May; 27(5):1580-6.
Score: 0.004
-
Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol. 2011 Jan; 77(1):12-9.
Score: 0.003
-
Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol. 2006 May 15; 176(10):6046-54.
Score: 0.003
-
Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S. CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol. 2006 Feb 15; 176(4):2307-15.
Score: 0.002
-
Wang X, Ko EC, Peng L, Gillies SD, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res. 2005 Aug 01; 65(15):6976-83.
Score: 0.002
-
Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol. 2005 Jun 01; 174(11):7104-10.
Score: 0.002
-
Wang X, Campoli M, Ko E, Luo W, Ferrone S. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004 Nov; 294(1-2):23-35.
Score: 0.002